Introduction and geographic availability of new antibiotics approved between 1999 and 2014.
BACKGROUND:Despite the urgent need for new, effective antibiotics, few antibiotics of value have entered the market during the past decades. Therefore, incentives have been developed to stimulate antibiotic R&D. For these incentives to be effective, geographic availability for recently approved...
Main Authors: | Cecilia Kållberg, Christine Årdal, Hege Salvesen Blix, Eili Klein, Elena M Martinez, Morten Lindbæk, Kevin Outterson, John-Arne Røttingen, Ramanan Laxminarayan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6191083?pdf=render |
Similar Items
-
The effect of generic market entry on antibiotic prescriptions in the United States
by: Cecilia Kållberg, et al.
Published: (2021-05-01) -
Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999–2005
by: Eili Klein, et al.
Published: (2007-12-01) -
Community-associated Methicillin-Resistant Staphylococcus aureus in Outpatients, United States, 1999–2006
by: Eili Klein, et al.
Published: (2009-12-01) -
The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study
by: Cecilia Kållberg, et al.
Published: (2023-03-01) -
Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations
by: Christine Årdal, et al.
Published: (2018-12-01)